Citadel Advisors
STLN

Citadel Advisors’s Starling Oncology STLN Stock Holding History

Citadel Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$404K Buy
74,400
+31,000
+71% +$130K ﹤0.01% 10397
2026
Q1 		$133K Buy
43,400
+16,600
+62% +$50.9K ﹤0.01% 11785
2025
Q4 		$95.4K Buy
26,800
+12,400
+86% +$46K ﹤0.01% 11682
2025
Q3 		$50.3K Buy
+14,400
New +$49.3K ﹤0.01% 12205

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's STLN Position: Q2 2026 in Review

Citadel Advisors increased its Starling Oncology (STLN) stake by 47% in Q2 2026, buying an estimated $1.2M and bringing the position to 894,101 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #4771.

Citadel Advisors first reported a position in STLN in Q1 2021 and has held it in 12 quarters since. The position peaked at $14.6M in Q3 2021. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Citadel Advisors held 894,101 shares of Starling Oncology worth $4.85M as of Q2 2026.
  • Citadel Advisors bought 285,834 Starling Oncology shares in Q2 2026, an estimated $1.2M.
  • Starling Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4771 holding.
  • Citadel Advisors first reported a position in Starling Oncology in Q1 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Starling Oncology position peaked at $14.6M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.